Table Info

Table 1.

Characterization and cytotoxic effect of precursor peptides in HeLa and Ca Ski cells after 2 h treatment at 37°C

Functional peptide	Sequence	RP-HPLC		ESI-MS (M)		IC₅₀ (μM)
Functional peptide	Sequence	t_R (min)	Purity (%)	Theorical	Experimental	HeLa	Ca Ski
Anticancer peptides (ACP)	RWQWRWQWR	6.6	98.1	1,485.76	1,485.78	47.6	> 134.5
	Ahx-RWQWRWQWR	6.5	97.6	1,598.85	1,598.88	103.3	> 125.0
	RWQWRWQWR-Ahx	7.1	98.6	1,598.85	1,598.86	> 125.0	> 125.0
	RRWQWR	5.3	99.3	985.55	985.58	> 202.0	> 202.0
	Ahx-RRWQWR	5.4	97.8	1,098.63	1,098.65	> 181.9	> 181.9
	RLLRRLLR	5.1	97.8	1,093.77	1,093.79	> 182.7	> 182.7
	Ahx-RLLRRLLR	5.9	97.3	1,206.85	1,206.87	> 165.6	> 165.6
Cervical cancer cell-targeting peptides (CTP)	QQLPSSSTSTYP	4.0	90.7	1,293.62	1,293.65	> 154.5	> 154.5
	Ahx-QQLPSSSTSTYP	4.1	96.5	1,406.70	1,406.72	> 142.1	> 142.1
	GDALFSVPLEVY	7.1	98.7	1,307.68	1,308.20	> 152.8	> 152.8
	Ahx-GDALFSVPLEVY	7.2	98.2	1,420.76	1,420.78	> 140.7	> 140.7
	QVNGLGERSQQM	3.8	86.2	1,344.66	1,344.67	> 148.6	> 148.6
	Ahx-QVNGLGERSQQM	4.0	93.1	1,457.74	1,457.76	> 137.1	> 137.1
	KQNLAEG	3.8^a	97.2	757.41	757.42	> 263.9	> 263.9
	Ahx-KQNLAEG	4.4^a	97.0	870.49	870.52	> 229.6	> 229.6
Cell-penetrating peptides (CPP)	YGRKKRPQRRR	3.8^a	99.2	1,498.92	1,498.92	> 133.4	> 133.4
	Ahx-YGRKKRPQRRR	4.4^a	94.5	1,612.00	1,612.04	> 124.0	> 124.0
	RRRRRRRR	4.0^a	96.7	1,265.84	1,265.84	> 157.9	> 157.9
	Ahx-RRRRRRRR	4.2^a	95.6	1,378.92	1,378.94	> 145.0	> 145.0
	RKKRRQRRR	3.7^a	93.8	1,337.88	1,337.90	> 149.4	> 149.4
	Ahx-RKKRRQRRR	3.8^a	98.2	1,450.97	1,450.98	> 137.8	> 137.8
	KLALKLALK	5.6	92.4	995.72	995.73	> 200.7	> 200.7
	Ahx-KLALKLALK	5.8	95.5	1,108.81	1,108.81	> 180.3	> 180.3

^a: RP-HPLC modified linear gradient (method 2). t_R: retention time; Ahx: 6-amino hexanoic acid; RP-HPLC: reverse phase-high performance liquid chromatography; ESI-MS: electrospray ionization-mass spectrometry. All peptides were obtained with amide function at the C-terminal end

Supplementary materials

The supplementary materials for this article are available at: https://www.explorationpub.com/uploads/Article/file/100864_sup_1.pdf.

Declarations

Author contributions

NAC: Conceptualization, Methodology, Investigation, Formal analysis, Writing—original draft, Visualization, Writing—review & editing. JEGC: Conceptualization, Methodology, Formal analysis, Resources, Writing—original draft, Visualization. CMPG: Formal analysis, Resources, Writing—original draft. YVC: Formal analysis, Resources, Writing—original draft. ACBC: Formal analysis, Resources, Writing—original draft. RFM: Conceptualization, Supervision. ZJRM: Conceptualization, Methodology, Resources, Writing—review & editing. JERM: Conceptualization, Methodology, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

This research was conducted with the financial support of MinCiencias with the project: “Obtención de un prototipo peptídico promisorio para el desarrollo de un medicamento de amplio espectro para el tratamiento del cáncer de colon, cuello uterino y próstata”. Contract RC No. 845-2019. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49. [DOI] [PubMed]

Cervical Cancer [Internet]. World Health Organization; c2024 [cited 2024 Jul 19]. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer

Cervical Cancer [Internet]. International Agency for Research on Cancer; c1965–2024. [cited 2024 Jul 19]. Available from: https://www.iarc.who.int/cancer-type/cervical-cancer/

Estimated number of deaths from 2022 to 2040, female, age [0–85+] [Internet]. International Agency for Research on Cancer; c1965–2024. [cited 2024 Jul 19]. Available from: https://gco.iarc.fr/tomorrow/en/dataviz/isotype?types=1&single_unit=100&cancers=23&years=2040&sexes=2&populations=170

Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2019;40:602–8. [DOI] [PubMed]

Burmeister CA, Khan SF, Schäfer G, Mbatani N, Adams T, Moodley J, et al. Cervical cancer therapies: Current challenges and future perspectives. Tumour Virus Res. 2022;13:200238. [DOI] [PubMed] [PMC]

Florea A, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011;3:1351–71. [DOI] [PubMed] [PMC]

Marqus S, Pirogova E, Piva TJ. Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci. 2017;24:21. [DOI] [PubMed] [PMC]

Erak M, Bellmann-Sickert K, Els-Heindl S, Beck-Sickinger AG. Peptide chemistry toolbox - Transforming natural peptides into peptide therapeutics. Bioorg Med Chem. 2018;26:2759–65. [DOI] [PubMed]

10.

Nhàn NTT, Yamada T, Yamada KH. Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions. Int J Mol Sci. 2023;24:12931. [DOI] [PubMed] [PMC]

11.

Chinnadurai RK, Khan N, Meghwanshi GK, Ponne S, Althobiti M, Kumar R. Current research status of anti-cancer peptides: Mechanism of action, production, and clinical applications. Biomed Pharmacother. 2023;164:114996. [DOI] [PubMed]

12.

Wang C, Yang C, Chen Y, Ma L, Huang K. Rational Design of Hybrid Peptides: A Novel Drug Design Approach. Curr Med Sci. 2019;39:349–55. [DOI] [PubMed]

13.

Wu D, Gao Y, Chen L, Qi Y, Kang Q, Wang H, et al. Anti-tumor effects of a novel chimeric peptide on S180 and H22 xenografts bearing nude mice. Peptides. 2010;31:850–64. [DOI] [PubMed]

14.

Ueyama H, Horibe T, Nakajima O, Ohara K, Kohno M, Kawakami K. Semaphorin 3A lytic hybrid peptide binding to neuropilin-1 as a novel anti-cancer agent in pancreatic cancer. Biochem Biophys Res Commun. 2011;414:60–6. [DOI] [PubMed]

15.

Chepurny OG, Bonaccorso RL, Leech CA, Wöllert T, Langford GM, Schwede F, et al. Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors. Sci Rep. 2018;8:3749. [DOI] [PubMed] [PMC]

16.

Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC Jr. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52:60–8. [DOI] [PubMed] [PMC]

17.

Horn M, Neundorf I. Design of a novel cell-permeable chimeric peptide to promote wound healing. Sci Rep. 2018;8:16279. [DOI] [PubMed] [PMC]

18.

Erbani SN, Madanchi H, Far HA, Rostamian M, Rahmati S, Shabani AA. First report of antifungal activity of CecropinA-Magenin2 (CE-MA) hybrid peptide and its truncated derivatives. Biochem Biophys Res Commun. 2021;549:157–63. [DOI] [PubMed]

19.

Kim Y, Kim N, Lee J, Jang J, Park Y, Park S, et al. Novel chimeric peptide with enhanced cell specificity and anti-inflammatory activity. Biochem Biophys Res Commun. 2015;463:322–8. [DOI] [PubMed]

20.

Barragán-Cárdenas A, Insuasty-Cepeda DS, Niño-Ramírez VA, Umaña-Pérez A, Ochoa-Zarzosa A, López-Meza JE, et al. The Nonapeptide RWQWRWQWR: A Promising Molecule for Breast Cancer Therapy. ChemistrySelect. 2020;5:9691–700. [DOI]

21.

Barragán-Cárdenas A, Urrea-Pelayo M, Niño-Ramírez VA, Umaña-Pérez A, Vernot JP, Parra-Giraldo CM, et al. Selective cytotoxic effect against the MDA-MB-468 breast cancer cell line of the antibacterial palindromic peptide derived from bovine lactoferricin. RSC Adv. 2020;10:17593–601. [DOI] [PubMed] [PMC]

22.

Solarte VA, Rosas JE, Rivera ZJ, Arango-Rodríguez ML, García JE, Vernot J. A Tetrameric Peptide Derived from Bovine Lactoferricin Exhibits Specific Cytotoxic Effects against Oral Squamous-Cell Carcinoma Cell Lines. Biomed Res Int. 2015;2015:630179. [DOI] [PubMed] [PMC]

23.

Cárdenas-Martínez KJ, Barragán-Cárdenas AC, Rosa-Arbeláez Mdl, Parra-Giraldo CM, Ochoa-Zarzosa A, Lopez-Meza JE, et al. Evaluating the In Vitro Activity and Safety of Modified LfcinB Peptides as Potential Colon Anticancer Agents: Cell Line Studies and Insect-Based Toxicity Assessments. ACS Omega. 2023;8:37948–57. [DOI] [PubMed] [PMC]

24.

Barragán-Cárdenas AC, Insuasty-Cepeda DS, Cárdenas-Martínez KJ, López-Meza J, Ochoa-Zarzosa A, Umaña-Pérez A, et al. LfcinB-Derived Peptides: Specific and Punctual Change of an Amino Acid in Monomeric and Dimeric Sequences Increase Selective Cytotoxicity in Colon Cancer Cell Lines. Arabian J Chem. 2022;15:103998. [DOI]

25.

Lee HS, Park CB, Kim JM, Jang SA, Park IY, Kim MS, et al. Mechanism of Anticancer Activity of Buforin IIb, a Histone H2A-Derived Peptide. Cancer Lett. 2008;271:47–55. [DOI]

26.

Cepeda DSI, Castañeda HMP, Mayor AVR, Castañeda JEG, Villamil MM, Medina RF, et al. Synthetic Peptide Purification via Solid-Phase Extraction with Gradient Elution: A Simple, Economical, Fast, and Efficient Methodology. Molecules. 2019;24:1215. [DOI] [PubMed] [PMC]

27.

Rodriguez Guerra J, Barragán Cárdenas A, Ochoa-Zarzosa A, Meza JL, Pérez AU, Fierro-Medina R, et al. The tetrameric peptide LfcinB (20-25)₄ derived from bovine lactoferricin induces apoptosis in the MCF-7 breast cancer cell line. RSC Adv. 2019;9:20497–504. [DOI] [PubMed] [PMC]

28.

Aguirre-Guataqui K, Márquez-Torres M, Pineda-Castañeda HM, Vargas-Casanova Y, Ceballos-Garzon A, Rivera-Monroy ZJ, et al. Chimeric Peptides Derived from Bovine Lactoferricin and Buforin II: Antifungal Activity against Reference Strains and Clinical Isolates of Candida spp. Antibiotics (Basel). 2022;11:1561. [DOI] [PubMed] [PMC]

29.

Sæbø IP, Bjørås M, Franzyk H, Helgesen E, Booth JA. Optimization of the Hemolysis Assay for the Assessment of Cytotoxicity. Int J Mol Sci. 2023;24:2914. [DOI] [PubMed] [PMC]

30.

Robles-Loaiza AA, Pinos-Tamayo EA, Mendes B, Ortega-Pila JA, Proaño-Bolaños C, Plisson F, et al. Traditional and Computational Screening of Non-Toxic Peptides and Approaches to Improving Selectivity. Pharmaceuticals (Basel). 2022;15:323. [DOI] [PubMed] [PMC]

31.

Tang L. Investigating heterogeneity in HeLa cells. Nat Methods. 2019;16:281. [DOI] [PubMed]

32.

Wong RSY. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30:87. [DOI] [PubMed] [PMC]

33.

Richardson A, Antueno Rd, Duncan R, Hoskin DW. Intracellular delivery of bovine lactoferricin’s antimicrobial core (RRWQWR) kills T-leukemia cells. Biochem Biophys Res Commun. 2009;388:736–41. [DOI] [PubMed]

34.

Hilchie AL, Vale R, Zemlak TS, Hoskin DW. Generation of a hematologic malignancy-selective membranolytic peptide from the antimicrobial core (RRWQWR) of bovine lactoferricin. Exp Mol Pathol. 2013;95:192–8. [DOI] [PubMed]

35.

Pan W, Chen P, Chen YS, Hsu H, Lin C, Chen W. Bovine lactoferricin B induces apoptosis of human gastric cancer cell line AGS by inhibition of autophagy at a late stage. J Dairy Sci. 2013;96:7511–20. [DOI] [PubMed]

36.

Kondo E, Iioka H, Saito K. Tumor-homing peptide and its utility for advanced cancer medicine. Cancer Sci. 2021;112:2118–25. [DOI] [PubMed] [PMC]

37.

Liu X, Peng J, He J, Li Q, Zhou J, Liang X, et al. Selection and identification of novel peptides specifically targeting human cervical cancer. Amino Acids. 2018;50:577–92. [DOI] [PubMed]

38.

Li G, Yin Q, Ji H, Wang Y, Liu H, Jiang L, et al. A study on screening and antitumor effect of CD55-specific ligand peptide in cervical cancer cells. Drug Des Devel Ther. 2018;12:3899–912. [DOI] [PubMed] [PMC]

39.

Li C, Gao N, Xue Q, Ma N, Hu Y, Zhang J, et al. Screening and identification of a specific peptide binding to cervical cancer cells from a phage-displayed peptide library. Biotechnol Lett. 2017;39:1463–9. [DOI] [PubMed]

40.

Bechara C, Sagan S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett. 2013;587:1693–702. [DOI] [PubMed]

41.

Borrelli A, Tornesello AL, Tornesello ML, Buonaguro FM. Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents. Molecules. 2018;23:295. [DOI] [PubMed] [PMC]

42.

Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today. 2012;17:850–60. [DOI] [PubMed]

43.

Ma Y, Gong C, Ma Y, Fan F, Luo M, Yang F, et al. Direct cytosolic delivery of cargoes in vivo by a chimera consisting of D- and L-arginine residues. J Control Release. 2012;162:286–94. [DOI] [PubMed]

44.

Song J, Zhang Y, Zhang W, Chen J, Yang X, Ma P, et al. Cell penetrating peptide TAT can kill cancer cells via membrane disruption after attachment of camptothecin. Peptides. 2015;63:143–9. [DOI] [PubMed]

45.

Ramírez-Sánchez DA, Arredondo-Beltrán IG, Canizalez-Roman A, Flores-Villaseñor H, Nazmi K, Bolscher JGM, et al. Bovine lactoferrin and lactoferrin peptides affect endometrial and cervical cancer cell lines. Biochem Cell Biol. 2021;99:149–58. [DOI] [PubMed]

46.

Hilchie AL, Hoskin DW, Coombs MRP. Anticancer Activities of Natural and Synthetic Peptides. Adv Exp Med Biol. 2019;1117:131–47. [DOI] [PubMed]

47.

Ruseska I, Zimmer A. Internalization mechanisms of cell-penetrating peptides. Beilstein J Nanotechnol. 2020;11:101–23. [DOI] [PubMed] [PMC]

48.

Zhou M, Zou X, Cheng K, Zhong S, Su Y, Wu T, et al. The role of cell-penetrating peptides in potential anti-cancer therapy. Clin Transl Med. 2022;12:e822. [DOI] [PubMed] [PMC]

49.

Chiangjong W, Chutipongtanate S, Hongeng S. Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review). Int J Oncol. 2020;57:678–96. [DOI] [PubMed] [PMC]

50.

Oddo A, Hansen PR. Hemolytic Activity of Antimicrobial Peptides. Methods Mol Biol. 2017;1548:427–35. [DOI] [PubMed]

51.

Cárdenas-Martínez KJ, Grueso-Mariaca D, Vargas-Casanova Y, Bonilla-Velásquez L, Estupiñán SM, Parra-Giraldo CM, et al. Effects of Substituting Arginine by Lysine in Bovine Lactoferricin Derived Peptides: Pursuing Production Lower Costs, Lower Hemolysis, and Sustained Antimicrobial Activity. Int J Pept Res Ther. 2021;27:1751–62. [DOI]